TABLE 1.
Overview of Included Studies
| Title | Year | Country | Type of Study | N patients | Disease | Intervention | Intervention Duration | PROMs Used |
|---|---|---|---|---|---|---|---|---|
| Medical | ||||||||
| Keimpema et al9 | 2009 | Netherlands and Belgium | Randomized controlled trial | 54 | ADPKD and ADPLD | Lanreotide 120 mg/4 wk | 6 mo | SF-36 GI questionnaire |
| Hogan et al10 | 2010 | USA | Randomized controlled trial | 42 | ADPKD and ADPLD | Octreotide 40 mg/4 wk | 12 mo | SF-36 |
| Gevers et al11 | 2015 | Netherlands | Prospective cohort | 43 | ADPKD | Lanreotide 120 mg/4 wk | 6 mo | EQ-5D GI questionnaire |
| Aerts et al12 | 2019 | Netherlands | Randomized controlled trial | 175 | ADPKD | Lanreotide 120 mg/4 wk | 120 weeks | GI questionnaire |
| Hogan et al13 | 2020 | USA | Randomized controlled trial | 48 | ADPKD and ADPLD | Pasireotide 60 mg/4 wk | 12 mo | SF-36 GI questionnaire |
| Chrispijn et al14 | 2013 | Netherlands | Randomized controlled trial | 44 | ADPKD and ADPLD | Octreotide 40 mg/4 wk and everolimus 2.5 mg/daily | 12 mo | EQ-5D GI questionnaire |
| Anderegg et al15 | 2020 | Switzerland | Prospective cohort | 38 | ADPKD and ADPLD | Tolvaptan 90/30 mg/daily | 12 mo | KDQOL-SF |
| D’angolo et al16 | 2016 | Spain and Netherlands | Randomized controlled trial | 34 | ADPLD | Ursochol 15–20 mg/kg/day | 24 weeks | SF-36 EQ-VAS EORTC-QLQ-c30 PLD-Q |
| Radiologic | ||||||||
| Benzimra et al17 | 2014 | France | Retrospective cohort | 57 | Symptomatic hepatic cysts | AS | N/A | Self-designed questionnaire |
| Neijenhuis et al8 | 2019 | Netherlands | Randomized controlled trial | 32 | Symptomatic hepatic cysts | AS | N/A | PLD-Q |
| Surgical | ||||||||
| Schnelldorfer et al5 | 2009 | USA | Retrospective cohort | 141 | ADPKD and ADPLD | Mixed (CF/resection/LT) | N/A | SF-36 Symptom status ECOG-PS |
| Ogawa et al18 | 2014 | Japan | Retrospective cohort | 202 | ADPLD | Mixed (AS/CF/resection/LT) | N/A | ECOG-PS |
| Keimpema et al19 | 2008 | Netherlands | Prospective cohort | 12 | ADPLD | CF | N/A | GI questionnaire |
| Bernts et al6 | 2020 | USA | Prospective cohort | 18 | ADPLD | PHCF | N/A | SF-12 EQ-VAS PLD-Q |
| Boillot et al20 | 2021 | France | Retrospective cohort | 29 | ADPLD | PHCF | N/A | ECOG-PS |
| Kirchner et al21 | 2006 | Germany | Retrospective cohort | 36 | ADPKD and ADPLD | CKLT | N/A | SF-36 Self-designed questionnaire |
| Ding et al22 | 2019 | China | Retrospective cohort | 11 | ADPLD | LT | N/A | SF-36 ECOG-PS |
ADPKD indicates autosomal dominant polycystic kidney disease; ADPLD, autosomal dominant polycystic liver disease; AS, aspiration sclerotherapy; CF, cyst fenestration; CKLT, combined kidney-liver transplantation; ECOG-PS, Eastern Cooperative Oncology Group Performance Status; EORTC-QLQ-c30, European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire; EQ-5D, EuroQol 5 Dimensions; EQ-VAS, EuroQol-visual analog scales; GI, gastrointestinal; KDQOL-SF, Kidney Disease and Quality of Life - Short Form; kg, kilograms; LT, liver transplantation; mg, milligram; N/A, not applicable; PHCF, partial hepactomy and cyst fenestration; PLD-Q, polycystic liver disease questionnaire; SF-36, short-form 36; wk, weeks.